Monopar Therapeutics Files 8-K

Ticker: MNPR · Form: 8-K · Filed: 2025-05-07T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, disclosure

TL;DR

Monopar Therapeutics filed an 8-K, signaling a material event. Details pending.

AI Summary

Monopar Therapeutics Inc. filed an 8-K on May 7, 2025, reporting an event that occurred on the same date. The filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. No specific details regarding the nature of the event or any financial transactions were provided in the excerpt.

Why It Matters

This filing indicates a material event has occurred for Monopar Therapeutics, requiring public disclosure. Investors should look for subsequent filings or press releases for details.

Risk Assessment

Risk Level: low — The filing itself is a standard procedural disclosure and does not contain information that inherently increases risk.

Key Players & Entities

FAQ

What specific event triggered this 8-K filing for Monopar Therapeutics?

The provided excerpt does not specify the exact event that triggered the 8-K filing; it only states the date of the earliest event reported as May 7, 2025.

When was this 8-K filed with the SEC?

This 8-K was filed on May 7, 2025.

What is the principal business address of Monopar Therapeutics?

The principal executive offices of Monopar Therapeutics are located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.

What is the trading symbol for Monopar Therapeutics?

The excerpt mentions 'Trading Symbol(s)' but does not list the specific symbol for Monopar Therapeutics.

Under which section of the Securities Exchange Act is this report filed?

This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.

From the Filing

0001437749-25-014880.txt : 20250507 0001437749-25-014880.hdr.sgml : 20250507 20250507060058 ACCESSION NUMBER: 0001437749-25-014880 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20250507 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250507 DATE AS OF CHANGE: 20250507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 25919085 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 8-K 1 mnpr20250505_8k.htm FORM 8-K mnpr20250505_8k.htm false 0001645469 0001645469 2025-05-07 2025-05-07     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): May 7, 2025   MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter)   Delaware   001-39070   32-0463781 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   1000 Skokie Blvd. , Suite 350 , Wilmette , IL   60091 (Address of principal executive offices)   (Zip Code)   ( 847 ) 388-0349 Registrant’s telephone number, including area code   N/A (Former name or former address, if changed since last report)   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.001 par value   MNPR   The Nasdaq Stock Market LLC (Nasdaq Capital Market)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company  ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐           Item 7.01   Regulation FD Disclosure     On May 7, 2025, Monopar Therapeutics Inc. (Monopar) issued a press release announcing a poster presentation of data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease at the European Association for the Study of the Liver (“EASL”) International Liver Congress 2025.   The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.   Item 9.01 Financial Statements and Exhibits   Exhibit No.      Description 99.1   Press Release

View on Read The Filing